Vir Biotechnology Stock News

Vir Biotechnology, Inc. (NASDAQ:VIR)s share price gapped up before the market opened on Monday . The stock had previously closed at $53.92, but opened at $56.50. Vir Biotechnology shares last traded at $52.25, with a volume of 14,568 shares. A number of brokerages have weighed in on VIR. Needham & Company LLC reissued a buy []

Vir Biotechnology (NASDAQ:VIR) had its price objective hoisted by HC Wainwright from $200.00 to $300.00 in a research note issued to investors on Tuesday morning, Price Targets.com reports. HC Wainwright currently has a buy rating on the stock. Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. upgraded Vir []

Vir Biotechnology and CytRx are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst

Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Volatility and Risk Vir Biotechnology has a beta of -1.48, indicating that its stock price is 248% [] The post Financial Survey: Vir Biotechnology (NASDAQ:VIR) vs. CytRx (OTCMKTS:CYTR) appeared first on ETF Daily News .

We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.

This article was originally published on TipRanks.com Commercial-stage immunology company Vir Biotechnology, Inc. The post Vir Biotechnology & GlaxoSmithKlines Sotrovimab Receives Marketing Authorization From EU appeared first on Smarter Analyst .

Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Profitability This table compares Vir Biotechnology and CytRxs net margins, return on equity and return on assets. [] The post Vir Biotechnology (NASDAQ:VIR) and CytRx (OTCMKTS:CYTR) Critical Contrast appeared first on ETF Daily News .

Wall Street analysts expect Vir Biotechnology, Inc. (NASDAQ:VIR) to announce $124.06 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Vir Biotechnologys earnings, with estimates ranging from $123.90 million to $124.21 million. Vir Biotechnology posted sales of $1.73 million in the same quarter last year, []

Vir Biotechnology, Inc. (NASDAQ:VIR) has been assigned a consensus rating of Hold from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price []

The immunology specialist says it can help combat omicron.

The immunology specialist says it can help combat omicron.

Gainers Nxt-ID, Inc. (NASDAQ: NXTD ) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers. Biofrontera Inc. (NASDAQ: BFRI ) shares climbed 27.6% to $7.02 after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target. CMC Materials, Inc. (NASDAQ: CCMP ) surged 25.9% to $183.74 after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock. Insignia Systems, Inc. (NASDAQ: ISIG ) surged 21.2% to $20.18. Gemini Therapeutics, Inc. (NASDAQ: GMTX ) gained 21% to $2.94 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target. mCloud Technologies Corp. (NASDAQ: MCLD ) jumped 17.2% to $4.6405 after the company signed a cloud agreement with Virtual Vision to host AssetCare customers in Saudi Arabia. Vir Biotechnology, Inc. (NASDAQ: VIR ) gained 15.2% to $53.03 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.

Vir Biotechnology Inc (NASDAQ: VIR) announced new preclinical data, published to the preprint server  bioRxiv , demonstrating the impact of the significant antigenic shift of the new COVID-19 omicr

Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron SAN FRANCISCO , Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc.

NEW YORK , Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VIR, PFE, AAPL, TSLA, and AMC. Full story available on Benzinga.com